Voriconazole therapeutic drug monitoring

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 4, 2006, Pages 1570-1572

  Smith, J ^a   Safdar, N ^a   Knasinski, V ^a   Simmons, W ^b   Bhavnani, S M ^c   Ambrose, P G ^c   Andes, D ^a,b,d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c ORDWAY RESEARCH INSTITUTE   (United States)

^d Department of Medical Microbiology and Immunology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCYTOSINE; ITRACONAZOLE; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; BLASTOMYCOSIS; BONE MARROW TRANSPLANTATION; CANDIDIASIS; CLINICAL ARTICLE; CRYPTOCOCCOSIS; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG MONITORING; FEBRILE NEUTROPENIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MYCOSIS; PRIORITY JOURNAL; THERAPEUTIC DRUG MONITORING; TREATMENT OUTCOME;

ADULT; AGED; ANTIFUNGAL AGENTS; DISEASE PROGRESSION; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRIMIDINES; RETROSPECTIVE STUDIES; TRIAZOLES;

EID: 33645761890     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.4.1570-1572.2006     Document Type: Article

References (29)

1. Alexander, B., W. A. Schell, J. L. Miller, G. D. Long, and J. R. Perfect. 2005. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 27:868-871.
2. Ambrose, P. G., D. M. Grasela, T. H. Grasela, J. Passarell, H. B. Mayer, and P. F. Pierce. 2001. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 45:2793-2797.
3. Begg, E. J., B. L. Murray, and C. J. Kirkpatrick. 1999. The therapeutic monitoring of antimicrobial agents. Br. J. Clin. Pharmacol. 47:23-30.
4. Craig, W. A., and D. Andes. 1996. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr. Infect. Dis. J. 15:255-259.
5. Desta, Z., X. Zaho, J. G. Shin, and D. A. Flockhart. 2002. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41:913-958.
6. Europen Medicines Agency. 2002. EPAR for Vfend. Europen Medicines Agency, London, United Kingdom.
7. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
8. Francis, P., and T. J. Walsh. 1992. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy; Clin. Infect. Dis. 15:1003-1018.
9. Glasmacher, A., C. Hahn, C. Leutner, E. Molitor, E. Wardelmann, C. Losem, T. Sauerbruch, G. Marklein, and I. G. Schmidt-Wolf. 1999. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 42:443-451.
10. Goldstein, J. A., and S. M. F. de Morais. 1994. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4:285-299.
11. Herbrecht, R., D. W. Denning, T. F. Patterson, J. E. Bennett, R. E. Greene, J. W. Oestmann, W. V. Kern, K. A. Marr, P. Ribaud, O. Lortholary, R. Sylvester, R. H. Rubin, J. R. Wingard, P. Stark, C. Durand, D. Caillot, E. Thiel, P. H. Chandrasekar, M. R. Hodges, H. T. Schlamm, P. F. Troke, and B. de Pauw. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.
12. Hyland, R., B. C. Jones, and D. A. Smith. 2003. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab. Dispos. 31:540-712.
13. Ikeda, Y., K. Umemura, K. Kondo, K. Sekiguchi, and M. Nakashima. 2004. Pharmacokinetics of voriconazole and cytocrome P450 and 2C19 genetic status. Clin. Pharmacol. Ther. 75:586-588.
14. Imhof, A., S. A. Balajee, D. N. Fredricks, J. A. Englund, and K. A. Marr. 2004. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin. Infect. Dis. 39:743-746.
15. Lampe, D., S. Kreutzberg, and H. J. Prumke. 1994. Therapeutic drug monitoring of itraconazole-a report of experiences. Mycoses 37(Suppl. 2):34-39.
16. Lazarus, H. M., J. L. Blumer, S. Yanovich, H. Schlamm, and A. Romero. 2002. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J. Clin. Pharmacol. 42:395-402.
17. Lazo de la Vega, S., P. Volkow, R. A. Yeates, and G. Pfaff. 1994. Administration of the antimycotic agents fluconazole and itraconazole to leukaemia patients: a comparative pharmacokinetic study. Drugs Exp. Clin. Res. 20:69-75.
18. Lehman, D. F., J. J. Medicis, and P. D. Franklin. 2003. Polymorphisms and the pocketbook: the cost-effectiveness of cytochrome P450 2c19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcer. J. Clin. Pharmacol. 43:1316-1323.
19. Lutsar, I., M. R. Hodges, K. Tomaszewski, P. F. Troke, and N. Wood. 2003. The safety of voriconazole and dose individualization. Clin. Infect. Dis. 36:1087-8813.
20. Marty, F. M., L. A. Cosimi, and L. Baden. 2004. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N. Engl. J. Med. 350:950-952.
21. Petersen, D., S. Demertzis, M. Freund, G. Schumann, and M. Oellerich. 1994. Individualization of 5-fluorocytosine therapy. Chemotherapy 40:149-156.
22. Poirier, J. M., and G. Cheymol. 1998. Optimization of itraconazole therapy using target drug concentrations. Clin. Pharmacokinet 35:461-473.
23. Potoski, B. A., and J. R. Brown. 2002. The safety of voriconazole. Clin. Infect. Dis. 35:1273-1275.
24. Purkins, L., N. Wood, K. Greenhalgh, M. J. Allen, and S. D. Oliver. 2003. Voriconazole, a novel wide spectrum triazole: oral pharmacokinetics and safety. Br. J. Clin. Pharmacol. 56(Suppl. 1):10-16.
25. Purkins, L., N. Wood, P. Ghahramani, K. Greenhalgh, M. J. Allen, and D. Kleinermans. 2002. Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46:2546-2553.
26. Radford, S. A., E. M. Johnson, and D. W. Warnock. 1997. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less common mold pathogens. Antimicrob. Agents Chemother. 41:841-843.
27. Schafer-Korting, M. 1993. Pharmacokinetic optimization of oral antifungal therapy. Clin. Pharmacokinet. 25:329-341.
28. Service, R. F. 2005. Going from genome to pill. Science 308:1858-1860.
29. Siwek, G. T., K. J. Dodgson, M. de Magalhaes-Silvermanet, L. A. Bartlet, S. B. Kilborn, P. L. Hoth, D. J. Diekema, and M. A. Pfaller. 2004. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin. Infect. Dis. 39:584-587.